Poster presented at EHA2023 outlining an updated analysis of a Phase 2 study evaluating the efficacy and safety of a BTKi in combination with an anti-CD20 monoclonal antibody in patients with relapsed/refractory (R/R) follicular lymphoma (FL).

Chat with BeiGene

Close